Breathe Well Live Well
 InPharm |
GSK severe asthma drug progresses to Phase III
InPharm The Phase IIb DREAM study was testing mepolizumab in patients with severe eosinophilic asthma, a condition where organs are damaged by the over-production of white blood cells. The year-long study, which involved 621 patients, found the number of … GSK asthma drug cuts symptoms 52%; ready for PhIII GSK drug halves attacks in hard-to-treat asthma Drug 'could cut asthma A&E visits' |
View full post on asthma – Google News
 InPharm |
Pipeline Progresses at Glaxo/THRX – Analyst Blog
NASDAQ The companies also completed the phase III Breo registrational program for the treatment of persistent asthma in adults and adolescents. Positive results were reported from a study evaluating the efficacy and safety of fluticasone furoate and … GSK and Theravance file for FF/VI approval in the USA and Europe; Talks with … GSK, Theravance seek approvals for FF/VI in US, Europe GSK and Theravance file COPD drug |
View full post on asthma – Google News
InPharm |
Pipeline Progresses at Glaxo/THRX
InvestorIdeas.com (press release) In the EU, a regulatory application for asthma was also submitted. The COPD application in the US relates to the approval of Breo as long-term maintenance treatment of airflow obstruction in COPD patients, including chronic bronchitis and/or emphysema … GSK and Theravance file for FF/VI approval in the USA and Europe; Talks with … GSK, Theravance seek approvals for FF/VI in US, Europe GSK and Theravance file COPD drug |
View full post on asthma – Google News